Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.33.

A number of analysts recently weighed in on the company. Oppenheimer dropped their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 9th. Guggenheim restated a "buy" rating and set a $15.00 target price on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital decreased their target price on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, March 26th. Finally, HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ZURA. JPMorgan Chase & Co. raised its stake in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after purchasing an additional 2,611,532 shares during the period. ADAR1 Capital Management LLC boosted its holdings in shares of Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock worth $3,614,000 after purchasing an additional 723,933 shares during the period. Allostery Investments LP boosted its holdings in shares of Zura Bio by 44.2% in the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock worth $3,005,000 after purchasing an additional 714,258 shares during the period. Millennium Management LLC boosted its holdings in shares of Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company's stock worth $1,753,000 after purchasing an additional 657,420 shares during the period. Finally, Boxer Capital Management LLC purchased a new position in Zura Bio during the 4th quarter valued at $750,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Stock Performance

Shares of ZURA opened at $1.31 on Friday. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.07. The business has a 50-day moving average of $1.15 and a 200 day moving average of $1.41. The firm has a market cap of $89.57 million, a P/E ratio of -1.87 and a beta of -0.10.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). As a group, research analysts predict that Zura Bio will post -0.65 earnings per share for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.